CanSino Biologics explained

39.0739°N 117.543°W

CanSino Biologics Inc.
Trade Name:CanSinoBIO
Native Name:康希诺生物
Native Name Lang:zh-Hans
Predecessors:-->
Successors:-->
Founded: in Tianjin, China
Hq Location:185 South Avenue, TEDA West District
Hq Location City:Tianjin
Hq Location Country:China
Areas Served:-->
Profit:-->
Profit Year:-->
Owners:-->

CanSino Biologics, often abbreviated as CanSinoBIO, is a Chinese vaccine company.[1]

History

CanSino Biologics was founded in 2009 in Tianjin by Yu Xuefeng, Zhu Tao, Qiu Dongxu and Helen Mao Huihua.[1]

In July 2018, it filed an application to list on the Hong Kong Stock Exchange.[1] It debuted on 28 March 2019 with an increase of 59%, the highest first day trading gain in Hong Kong since 2017.[2] In August 2020, it completed a secondary offering on Shanghai Stock Exchange's STAR market where it raised 5.2 billion yuan (US$750 million).[3]

Vaccines

The company has a portfolio of vaccines under research including Ad5-EBOV to prevent Ebola and Ad5-nCoV for COVID-19.[1] [4] The company has previously collaborated with the National Research Council of Canada (NRC) on vaccine development. The two organizations began collaborating in 2013, and they later worked together to develop an Ebola vaccine.[5] [6] [7]

COVID-19 vaccine development

See main article: Convidecia.

AD5-nCOV, trade-named Convidecia, is a single-dose[8] viral vector COVID-19 vaccine developed by CanSino. Since late 2020, it has been in Phase III trials in Chile,[9] Mexico,[10] Pakistan,[11] Russia,[12] and Saudi Arabia with 40,000 participants.

In February 2021, global data from Phase III trials and 101 COVID cases showed that the vaccine had a 65.7% efficacy in preventing moderate symptoms of COVID-19, and 91% efficacy in preventing severe disease.[13] It has similar efficacy to the Janssen vaccine, another one-shot adenovirus vector vaccine with 66% efficacy in a global trial.[14] Its single-dose regimen and normal refrigerator storage requirement make it a favorable vaccine option for many countries. The vaccine is approved for emergency use listing by the WHO.[15]

In April 2021, CanSino Biologics began clinical trials for a version of its Covid-19 vaccine administered by inhalation rather than injection.[16] Rollout of inhaled boosters began in China in October 2022.[17]

Convidecia is approved for use by some countries in Asia,[18] [19] [20] Latin America,[21] [22] [23] and by Hungary.[24] [25] Production capacity for Ad5-NCov should reach 500 million doses in 2021. Manufacturing will take place in China,[26] Malaysia, Mexico,[27] and Pakistan.[28]

Investors

CanSino Biologics investors included Lilly Asia Ventures, Qiming Venture Partners and SDIC Fund Management.[1]

See also

Notes and References

  1. News: Ng. Eric. Chinese vaccine maker CanSino faces tough IPO sell in wake of Changsheng Bio-technology scandal. South China Morning Post. 25 July 2018. 18 April 2020.
  2. News: Low. Zoe. Ebola vaccine maker CanSino Biologics has a plan to take its life-saving treatments well beyond China's domestic market. South China Morning Post. 29 March 2019. 18 April 2020.
  3. News: Ren . Daniel . Covid-19 vaccine maker CanSino soars in Star Market debut . 15 August 2020 . South China Morning Post . 13 August 2020 . en.
  4. News: Pinghui. Zhuang. Volunteers needed for second phase of China coronavirus vaccine trial. South China Morning Post. Beijing. 10 April 2020. 18 April 2020.
  5. News: Canada . National Research Council . The National Research Council of Canada and CanSino Biologics Inc. announce collaboration to advance vaccine against COVID-19 . 19 May 2020 . www.newswire.ca . en.
  6. News: National Research Council contribution plays key role in newly approved Ebola vaccine. March 20, 2018. National Research Council Canada. The vaccine developed by CanSino is designed to provide protection against the strain of Ebola virus that caused the 2014 outbreak..
  7. Web site: Canada's surprising history and questionable partnership with a Chinese company and its military-backed COVID-19 vaccine. 2021-05-21. nationalpost. en-CA.
  8. Web site: It's not just Johnson & Johnson: China has a single-dose COVID-19 vaccine that's 65% effective. 2021-02-11. Fortune.
  9. Web site: Gob.cl - Article: Science Minister: "We Work With Maximum Rigor So That Science And Technology Benefit People'S Health". 2020-11-21. Government of Chile.
  10. Web site: 2020-11-10. Chinese Covid vaccine trials to be expanded to five more states. 2020-11-11. Mexico News Daily.
  11. Web site: Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above - Full Text View - ClinicalTrials.gov. 2020-10-21. clinicaltrials.gov.
  12. News: 2020-12-07. Russia approves clinical trials for Chinese COVID-19 vaccine Ad5-Ncov: Ifax. Reuters. 2020-12-07.
  13. Web site: 8 February 2021. CanSinoBIO's COVID-19 vaccine 65.7% effective in global trials, Pakistan official says. 2021-02-08. Reuters.
  14. News: 2021-02-08. China's CanSino Covid Vaccine Shows 65.7% Efficacy. Bloomberg.com. 2021-02-10.
  15. Web site: COVID-19 Vaccines with WHO Emergency Use Listing . WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control) . WHO . 10 April 2023 . en . 3 November 2021 . 21 December 2021 . https://web.archive.org/web/20211221213532/https://extranet.who.int/pqweb/vaccines/vaccinescovid-19-vaccine-eul-issued . dead .
  16. Web site: 2021-04-20. CanSino Biologics to start clinical trials of inhaled Covid-19 vaccine. 2022-02-15. Pharmaceutical Technology. en-US.
  17. Gao . Jiaxuan . Vaccination with CanSinoBIO's inhaled COVID-19 vaccine has begun in China . Journal of Biosafety and Biosecurity . December 2022 . 4 . 2 . 163 . 10.1016/j.jobb.2022.12.002 . 36589793 . 9791787 .
  18. News: Liu. Roxanne. 2021-02-25. China approves two more domestic COVID-19 vaccines for public use. Reuters. 2021-02-26.
  19. Web site: 2021-04-25. Pakistan purchases over 30 million COVID doses from China: sources. 2021-04-26. ARY NEWS. en-US.
  20. Web site: Malaysia to receive CanSino vaccine this month The Malaysian Insight. 2021-04-03. www.themalaysianinsight.com. en.
  21. News: 2021-02-11. 'Our gratitude always': From China's CanSino, Mexico welcomes biggest vaccine shipment yet. Reuters. 2021-02-11.
  22. Web site: 2021-06-11. Argentina issues emergency approval to China's single-dose Cansino COVID-19 vaccine. 2021-06-11. Reuters.
  23. Web site: ISP Approves Emergency Use And Importation Of Cansino Vaccine To Fight COVID-19. live. 2021-04-08. Institute of Public Health of Chile. https://web.archive.org/web/20210407194622/https://www.ispch.cl/noticia/isp-aprueba-uso-de-emergencia-e-importacion-de-la-vacuna-covid-19-de-laboratorio-cansino/ . 7 April 2021 .
  24. News: Ashok. Rashmi. 2021-03-22. UPDATE 2-China's CanSino Biologics COVID-19 vaccine receives emergency use approval in Hungary. Reuters. 2021-03-22.
  25. Web site: 2021-03-03. Membrii NITAG au venit cu recomandări privind utilizarea vaccinurilor împotriva COVID-19 în Republica Moldova. 2021-05-21. Ministerul Sănătății, Muncii și Protecţiei Sociale. en.
  26. Web site: China can hit 500-mln-dose annual capacity of CanSinoBIO COVID-19 vaccine this year. live. 2021-02-28. finance.yahoo.com. 27 February 2021 . https://web.archive.org/web/20210227110726/https://finance.yahoo.com/news/china-hit-500-mln-dose-103509138.html . 27 February 2021 .
  27. News: Solomon. Daina Beth. 2021-02-28. China's CanSino says first vaccines packaged in Mexico will be ready in March. Reuters. 2021-03-12.
  28. Web site: 2021-05-24. Pakistan develops homemade anti-Covid vaccine 'PakVac'. 2021-05-25. The Express Tribune. en.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "CanSino Biologics".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.